Holger Willenbring - Publications

Affiliations: 
Biomedical Sciences University of California, San Francisco, San Francisco, CA 
Area:
Cell Biology

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, Schwabe RF, Corvera CU, Grimm D, Willenbring H. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell. 18: 809-816. PMID 27257763 DOI: 10.1016/j.stem.2016.05.005  0.32
2016 Rezvani M, Grimm AA, Willenbring H. Assessing the therapeutic potential of lab-made hepatocytes. Hepatology (Baltimore, Md.). 64: 287-94. PMID 27014802 DOI: 10.1002/hep.28569  0.32
2016 Desai SS, Tung JC, Zhou VX, Grenert JP, Malato Y, Rezvani M, Español-Suñer R, Willenbring H, Weaver VM, Chang TT. Physiological Ranges of Matrix Rigidity Modulate Primary Mouse Hepatocyte Function In Part Through Hepatocyte Nuclear Factor 4 Alpha. Hepatology (Baltimore, Md.). PMID 26755329 DOI: 10.1002/hep.28450  0.32
2015 Mattis AN, Song G, Hitchner K, Kim RY, Lee AY, Sharma AD, Malato Y, McManus MT, Esau CC, Koller E, Koliwad S, Lim LP, Maher JJ, Raffai RL, Willenbring H. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology (Baltimore, Md.). 61: 141-52. PMID 25131933 DOI: 10.1002/hep.27379  0.32
2014 Hentzschel F, Hammerschmidt-Kamper C, Börner K, Heiss K, Knapp B, Sattler JM, Kaderali L, Castoldi M, Bindman JG, Malato Y, Willenbring H, Mueller AK, Grimm D. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2130-41. PMID 25189739 DOI: 10.1038/mt.2014.172  0.32
2014 Schaub JR, Malato Y, Gormond C, Willenbring H. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. Cell Reports. 8: 933-9. PMID 25131204 DOI: 10.1016/j.celrep.2014.07.003  0.32
2014 Espejel S, Eckardt S, Harbell J, Roll GR, McLaughlin KJ, Willenbring H. Brief report: Parthenogenetic embryonic stem cells are an effective cell source for therapeutic liver repopulation. Stem Cells (Dayton, Ohio). 32: 1983-8. PMID 24740448 DOI: 10.1002/stem.1726  0.32
2014 Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer CJ, Song G. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology (Baltimore, Md.). 60: 554-64. PMID 24677249 DOI: 10.1002/hep.27153  0.32
2014 Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 508: 93-7. PMID 24572354 DOI: 10.1038/nature13020  0.32
2014 Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, et al. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology (Baltimore, Md.). 59: 202-15. PMID 23913442 DOI: 10.1002/hep.26662  0.32
2013 Mathur A, Loskill P, Hong S, Lee J, Marcus SG, Dumont L, Conklin BR, Willenbring H, Lee LP, Healy KE. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Research & Therapy. 4: S14. PMID 24565415 DOI: 10.1186/scrt375  0.32
2013 Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, Tolstikov V, Wang C, McGee J, Khoobyari S, Nolta JA, Willenbring H, Zern MA. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Translational Medicine. 2: 409-19. PMID 23681950 DOI: 10.5966/sctm.2012-0160  0.32
2012 Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H. Cholangiocarcinomas can originate from hepatocytes in mice. The Journal of Clinical Investigation. 122: 2911-5. PMID 22797301 DOI: 10.1172/JCI63212  0.32
2012 Mattis AN, Willenbring H. A ZFN/piggyBac step closer to autologous liver cell therapy. Hepatology (Baltimore, Md.). 55: 2033-5. PMID 22422378 DOI: 10.1002/hep.25715  0.32
2012 Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. The Journal of Clinical Investigation. 122: 1097-108. PMID 22326957 DOI: 10.1172/JCI46039  0.44
2012 Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology (Baltimore, Md.). 55: 298-306. PMID 22030746 DOI: 10.1002/hep.24762  0.32
2011 Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring H. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. The Journal of Clinical Investigation. 121: 4850-60. PMID 22105172 DOI: 10.1172/JCI59261  0.32
2011 D'Alessio JA, Ng R, Willenbring H, Tjian R. Core promoter recognition complex changes accompany liver development. Proceedings of the National Academy of Sciences of the United States of America. 108: 3906-11. PMID 21368148 DOI: 10.1073/pnas.1100640108  0.32
2010 Malato Y, Willenbring H. The MAP3K TAK1: a chock block to liver cancer formation. Hepatology (Baltimore, Md.). 52: 1506-9. PMID 20879030 DOI: 10.1002/hep.23878  0.32
2010 Roll GR, Willenbring H. Transplanted nonviable human hepatocytes produce appreciable serum albumin levels in mice. Stem Cell Research. 5: 267-70. PMID 20829142 DOI: 10.1016/j.scr.2010.07.004  0.44
2010 Espejel S, Roll GR, McLaughlin KJ, Lee AY, Zhang JY, Laird DJ, Okita K, Yamanaka S, Willenbring H. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. The Journal of Clinical Investigation. 120: 3120-6. PMID 20739754 DOI: 10.1172/JCI43267  0.32
2010 Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H, Verdin E. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging. 2: 415-31. PMID 20634564 DOI: v2/n7/full/100176.html  0.32
2010 Song G, Sharma AD, Roll GR, Ng R, Lee AY, Blelloch RH, Frandsen NM, Willenbring H. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology (Baltimore, Md.). 51: 1735-43. PMID 20432256 DOI: 10.1002/hep.23547  0.44
2006 Bailey AS, Willenbring H, Jiang S, Anderson DA, Schroeder DA, Wong MH, Grompe M, Fleming WH. Myeloid lineage progenitors give rise to vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America. 103: 13156-61. PMID 16920790 DOI: 10.1073/pnas.0604203103  0.32
2006 Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, Grompe M, Fleming WH, Wong MH. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 6321-5. PMID 16606845 DOI: 10.1073/pnas.0508593103  0.32
2006 Vogel A, Aslan JE, Willenbring H, Klein C, Finegold M, Mount H, Thomas G, Grompe M. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. Gastroenterology. 130: 104-19. PMID 16401474 DOI: 10.1053/j.gastro.2005.10.012  0.32
Show low-probability matches.